Vigil Neuroscience Company Overview

Vigil Neuroscience logo
Vigil Neuroscience
Vigil Neuroscience primary media

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL) is dedicated to tackling neurodegenerative diseases by understanding and leveraging the power of microglia, the brain's primary immune cells. Their focused approach aims to develop treatments that can modify disease progression in conditions such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS). With a deep commitment to innovation, Vigil Neuroscience embarks on projects that explore the potential of microglial restoration and protection. The company's objective is to bring forth novel therapies that can significantly improve the lives of patients suffering from these debilitating diseases, providing hope through scientific advancement and dedicated research.

What is Vigil Neuroscience known for?

Snapshot

2020
Year founded
69
Employees
Watertown, United States
Head office
Loading Map...

Operations

All Locations
United States

Products and/or services of Vigil Neuroscience

  • Trem2 Agonists targeting Alzheimer's disease and other neurodegenerative disorders.
  • Antibody-based therapies for microglial restoration in central nervous system diseases.
  • Small molecule inhibitors for neuroinflammatory and neurodegenerative conditions.
  • Gene therapy approaches for the treatment of rare neurological diseases.
  • Biomarker identification and diagnostics development for neurodegenerative diseases.
  • Collaborative research programs with academic and industry partners for novel therapeutic discovery.

Vigil Neuroscience executive team

  • Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.President, CEO & Director
  • Ms. Jennifer Ziolkowski CPAChief Financial Officer
  • Dr. Petra Kaufmann M.D., M.S.Chief Medical Officer
  • Ms. Sharon MoraniSenior Director of Facilities & Operations
  • Dr. David Gray Ph.D.Chief Scientific Officer
  • Eric BrophySenior Manager of Information Technology
  • Ms. Leah GibsonVice President of Investor Relations & Corporate Communications
  • Ms. April Effort M.B.A., M.S.VP & Head of Corporate Development
  • Heidi Mizenko M.B.A.Senior Human Resources Associate
  • Mr. Evan A. Thackaberry DABT, Ph.D.Senior VP & Head of Early Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.